Concurrent dural and leptomeningeal metastatic carcinomatosis are very rare and have a poor prognosis. Here we present a woman with advanced estrogen receptor (ER) positive and progesterone receptor (PR) positive breast cancer who presented with leptomeningeal disease. Patient underwent multi targeted epigenetic therapies applied in a protocol called MTET. She continued to respond to the interval treatment, which consisted only of the nutraceutical agents. Here we discuss her case in detail and we believe that such an example might be applied to other patients in this situation resulting clinical improvement and less toxicity.
Introduction
Concurrent dural and leptomeningeal metastatic carcinomatosis are very rare and have a poor prognosis. In the literature, advanced breast carcinomas, bone-to-dura spread has been hypothesized to arise from dissemination of tu- If the tumor is small in size (less than 3 cm), Gamma knife stereotactic radiosurgery (GKRS) is an option. Gammaknife survival rates are similar to surgery plus whole brain radiation or whole brain radiation alone and are generally ineffective. The majority of patients progress despite systemic therapy and die in less than 6 months [1]- [7] .
Here we present a woman with advanced estrogen receptor (ER) positive and progesterone receptor (PR) positive breast cancer who presented with left facial paralysis, numbness to the chin and scalp, double vision, and severe headaches, then diagnosed with metastatic duraland leptomeningeal disease with possible intraparenchymal disease and involvement of the cavernous sinus, cranial fossa and microinvasion to brain parenchyma by the tumor.
Methods
The patient underwent combined systemic therapy by receiving a patented series of neutroceutical infusions consisting of called MTET (multi-targeted epigenetic therapy), along with GKRS, and minimal oral chemotherapy. She experienced a surprising overall improved physical response and radiological findings; all together it created a meaningful clinical response to the minimally toxic treatment.
With the MTET alone, she continued to respond to the interval treatment, which consisted only of the neutroceutical agents.
Discussion
Here we discuss her case in detail and we believe that such an example might be applied to other patients in this situation resulting clinical improvement and less toxicity. (please see Table 1 ). 
Case Study

Conclusion
The magnitude of response in this patient appears better than expected to the current standard of care outcome. Further trials are needed to support application of this novel combinational approach in advanced metastatic and leptomeningeal metastatic disease as a potential candidate for application for orphan drug designation.
